Table 1. Patient, Disease and Treatment Characteristics.
| Characteristics | N (%) |
|---|---|
| Subject-related | |
| N subjects | 4161 |
| Number of centers | 164 |
| Age at transplant, median (range), years | 57 (22-80) |
| < 40 years | 163 (4) |
| 40-49 years | 731(18) |
| 50-59 years | 1611 (39) |
| 60-69 years | 1427(34) |
| ≥ 70 years | 229 (6) |
| Male | 2437 (59) |
| Race | |
| Caucasian | 3159 (76) |
| African-American | 691 (17) |
| Hispanic | 172 (4) |
| Othersa | 78 (2) |
| Missing | 61 (1) |
| Karnofsky score < 90 | 1530 (37) |
| Body Mass Index (BMI) | |
| Underweight (<18.5) | 39 (1) |
| Normal weight (18.5-25) | 1045 (25) |
| Overweight (25-29.9) | 1607 (39) |
| Obesity (≥30) | 1449 (35) |
| Missing | 21 (<1) |
| History of smoking before transplant | 1821 (44) |
| Disease-related | |
| Stage III by Durie Salmon/International Stage | 2163 (52) |
| Immunochemical subtype of MM | |
| IgG | 2215 (53) |
| IgA | 803 (19) |
| Light chain | 730 (18) |
| Othersa | 51 (1) |
| Non-secretory | 177 (4) |
| Missing | 185 (4) |
| Albumin at diagnosis | |
| <3.5 g/dL | 1290 (31) |
| Creatinine at diagnosis >1.5 mg/dl | 959 (23) |
| Hemoglobin at diagnosis <10 g/dl | 2426 (58) |
| Treatment Characteristics | |
| Conditioning regimens | |
| Melphalan alone | 3388 (81) |
| Melphalan + TBI | 206 (5) |
| Melphalan + others (no TBI) | 245 (6) |
| Busulfan + Cyclophosphamide ± others | 231 (6) |
| Othersc | 91 (2) |
| Lines of chemotherapy pre transplant | |
| 1 | 2568 (62) |
| 2 | 1145 (28) |
| >2 | 419 (10) |
| Missing | 29(<1) |
| Pre-transplant radiation therapy | 1029 (26) |
| Chemotherapy prior to transplant | |
| Method I of description | |
| VAD/High dose steroids: Yes | 1684 (44) |
| Thalidomide: Yes | 1428(34) |
| Bortezomib: Yes | 880(21) |
| Lenalidomide: Yes | 565 (14) |
| Thalidomide + bortezomib: Yes | 321 (8) |
| Bortezomib + Lenalidomide: Yes | 393 (9) |
| Melphalan + Prednisone (MP): Yes | 266 (6) |
| Missing | 29 (<1) |
| Method II of description | |
| Thalidomide/lenalidomide + bortezomib | 619 (15) |
| Thalidomide/lenalidomide | 1288 (31) |
| Bortezomib | 261 (6) |
| VAD/high dose steroids | 1450 (35) |
| Melphalan + Prednisone (MP) | 127 (3) |
| Others | 387 (9) |
| Missing | 29 (<1) |
| Sensitive to pretransplant chemotherapy | 3425 (78) |
| Time from diagnosis to transplant, median (range), months | 7 (<1-18) |
| <6 months | 1123 (27) |
| 6-12 months | 2475 (59) |
| 12-18 months | 563 (14) |
| Transplant group | |
| Single autotransplant | 3196 (77) |
| ≥ 2 transplant, time interval between transplants <6 months | 615 (15) |
| ≥ 2 transplant, time interval between transplants ≥6 months | 350 (8) |
| Conditioning regimens | |
| Melphalan alone | 3388 (81) |
| Melphalan + TBI | 206 (5) |
| Melphalan + others (no TBI) | 245 (6) |
| Busulfan + cyclophosphamide ± others | 231 (6) |
| Othersc | 91 (2) |
| Year of transplant | |
| 1990-1995 | 132 (3) |
| 1996-1997 | 295 (7) |
| 1998-1999 | 367 (9) |
| 2000-2001 | 485 (12) |
| 2002-2003 | 438 (11) |
| 2004-2005 | 814 (20) |
| 2006-2007 | 651 (16) |
| 2008-2009 | 808 (19) |
| 2010 | 171 (4) |
| Planned maintenance therapy | |
| None | 2333 (56) |
| Thalidomide | 623 (15) |
| Bortezomib | 383 (9) |
| Lenalidomide | 450 (11) |
| Steroid | 180 (4) |
| Interferon | 234 (6) |
| Othersd | 160 (4) |
| Missing | 24 (<1) |
| Follow Up completeness Index @ 1 year & 5 years | 97% & 82% |
Abbreviations: VAD – Vincristine, Doxorubicin, Dexamethasone; SD – Stable Disease, TBI – Total body irradiation
Other race includes: Asian/Pacific islander (n=47), Native American (n=10), Middle Eastern White (n=7)
Other immunochemical type include: IgD (n=31), IgE (n=3), IgM (n=8)
Other conditioning regimens include: cyclophosphamide (n=12), cyclophosphamide+etopside (n=17), TBI (n=2), cyclophosphamide+taxol (n=1), cyclophosphamide+thiotepa(n=2), TBI+cyclophosphamide(n=29), TBI+Thiotepa (n=9), TBI+busulfan(n=3), TBI+etoposide(n=1), busulfan (n=5), busulfan+cytarabine+etoposide(n=1), busulfan+thiotepa (n=1), carboplatin+thiotepa (n=2).
Other maintenance therapy includes: rituxan (n=3), VP16 (n=2), IVIG (n=60), cyclophosphamide (N=26), doxil (n=2), biaxin (n=7), decadron (n=74), melphalan (n=18), taxol (n=13), cisp (n=10), etoposide (n=4), IL2 (n=26)